Adverum Biotechnologies Receivables 2013-2025 | ADVM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Adverum Biotechnologies receivables from 2013 to 2025. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Adverum Biotechnologies receivables from 2013 to 2025. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$248.3B
Amgen (AMGN)	$155.9B
Gilead Sciences (GILD)	$142.4B
Vertex Pharmaceuticals (VRTX)	$99.3B
Bristol Myers Squibb (BMY)	$96.1B
GSK (GSK)	$81.1B
CSL (CSLLY)	$67.7B
Regeneron Pharmaceuticals (REGN)	$62.3B
Alnylam Pharmaceuticals (ALNY)	$59.1B
Argenex SE (ARGX)	$43.3B
Insmed (INSM)	$27.9B
BioNTech SE (BNTX)	$25.2B
Royalty Pharma (RPRX)	$21B
Biogen (BIIB)	$20B
Incyte (INCY)	$16.4B
Genmab (GNMSF)	$16B
Genmab (GMAB)	$15.7B
Illumina (ILMN)	$15.2B
Ascendis Pharma (ASND)	$12B
BioMarin Pharmaceutical (BMRN)	$11B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
QIAGEN (QGEN)	$10.9B
Exelixis (EXEL)	$10.3B
Moderna (MRNA)	$9.6B
Verona Pharma American Depositary Share (VRNA)	$9.1B
Bio-Techne Corp (TECH)	$8.9B
Exact Sciences (EXAS)	$8.7B
Halozyme Therapeutics (HALO)	$8.5B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8.1B